1. Home
  2. CPF vs MNKD Comparison

CPF vs MNKD Comparison

Compare CPF & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Pacific Financial Corp New

CPF

Central Pacific Financial Corp New

HOLD

Current Price

$37.43

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.15

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPF
MNKD
Founded
1954
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2011
2004

Fundamental Metrics

Financial Performance
Metric
CPF
MNKD
Price
$37.43
$4.15
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$37.00
$8.69
AVG Volume (30 Days)
132.4K
4.8M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
3.39%
N/A
EPS Growth
45.18
N/A
EPS
1.58
N/A
Revenue
$51,817,000.00
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
$4.62
$11.89
P/E Ratio
$23.73
N/A
Revenue Growth
33.81
22.23
52 Week Low
$27.40
$2.23
52 Week High
$40.99
$6.51

Technical Indicators

Market Signals
Indicator
CPF
MNKD
Relative Strength Index (RSI) 39.53 56.27
Support Level $33.33 $3.74
Resistance Level $39.59 $4.55
Average True Range (ATR) 0.83 0.21
MACD -0.28 0.04
Stochastic Oscillator 17.37 77.92

Price Performance

Historical Comparison
CPF
MNKD

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: